Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q1 2025 Earnings Presentation
13 slides from Adc Therapeutics Sa's earnings presentation, May 14, 2025
Slide 1: 1Q 2025 Earnings Call
1Q 2025 Earnings Call May 14, 2025
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Introduction Mohamed Zaki 02 Chief Medical Officer Clinical Highlights Pepe Carmona Financial Update 03 Chief Financial Officer 04 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Key Business Updates
Key Business Updates Commercial § 1Q 2025 net product revenues of $17.4 million as compared to $17.8 million in same quarter 2024 Performance § Total 1Q revenue was $23.0 million including license revenues and royalties of $5.6 million § LOTIS-7 accepted for EHA2025 and ICML presentations • Abstract
Slide 5: Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas DLBCL FL MZL POTENTIAL TO MOVE INTO 2L+ DLBCL → LOTIS-5 (ZYNLONTA + rituximab): 20 patient safety run-in data showing ORR of 80%, CR of 50% with no new safety signals, completed enrollment in 1L 20241 → LOTIS-7 (ZYNLONTA + glofitamab): Promisi
Slide 6: LOTIS-7: Phase 1b Trial of ZYNLONTA in Combination with Glofitamab
LOTIS-7: Phase 1b Trial of ZYNLONTA in Combination with Glofitamab Screening Treatment Period Period (≤28 d) (cycles of 21 days) Study Population § Relapsed or Refractory B-NHL patients, ECOG PS 0 – 2, Escalating doses of and have received: 120, and 150 µg/kg) (ZYNLONTA 90, ZYNLONTA IV + glofitamab
Slide 7: LOTIS-7 Phase 1b Trial: Demographics and Safety Summary
CORPORATE LOTIS-7 Phase 1b Trial: Demographics and Safety Summary All Treated NHL Population* (N=31) as of January 17, 2025 Safety Summary N=31 Select Demographics N=31 CRS and ICANS Median age 73 CRS Grade 1 / 2 29.0% / 9.7% ≥2 prior therapies 61.3% ICANS Grade 1 / 2 0% / 6.5% Prior CAR-T Therapy 1
Slide 8: LOTIS-7 Phase 1b Trial: Efficacy Summary
LOTIS-7 Phase 1b Trial: Efficacy Summary Efficacy Evaluable Populationa (N=22) as of January 17, 2025 Glofit + Lonca Glofit + Lonca Total 120 µg/kg 150 µg/kg Best overall responsea n=11 (%) n=11 (%) n=22 (%) Overall Response Rate (CR + PR) 10 (90.9) 11 (100) 21 (95.5) Complete Response (CR)* 10 (90.
Slide 9: Upcoming LOTIS-7 Data Presentations
CORPORATE Upcoming LOTIS-7 Data Presentations EHA2025 poster presentation with updated data Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Session Date and Time: Saturday, June
Slide 10: 1Q 2025 Selected Financial Data
1Q 2025 Selected Financial Data Balance Sheet March 31, 2025 Cash and cash equivalents ($M) 194.7* Statement of Operations 1Q 2025 ($M) 1Q 2024 ($M) YoY % Product Revenues, Net 17.4 17.8 -2.5 Total Revenue 23.0 18.1 27.6 Total Operating Expenses 51.5 51.7 -0.3 Adjusted Total Operating Expenses (Non-
Slide 11: Delivering On Our Strategy
Delivering On Our Strategy Upcoming Expected Milestones 1H2025 2H2025 1H2026 Enrolled 40 patients Share fuller/more mature data ZYNLONTA LOTIS-7 Share additional data at Engage regulatory agencies, evaluate compendia strategies EHA, ICML ZYNLONTA Reach prespecified number of Potential BLA submission
Slide 12: Thank You
Thank You ® THERAPEUTICS Innovating Science. Inspiring Hope.
Slide 13: Reconciliation of GAAP Measures to Non-GAAP Measures
Reconciliation of GAAP Measures to Non-GAAP Measures Unaudited (in thousands) i. Share-based compensation expense (reversal) represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted, and is recognize